You are here

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Last updated on October 17, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hepatic Impairment
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy or hepatically impaired female subjects of non-child bearing potential and/or
male subjects who, at the time of Screening, are between the ages of 18 and 75 years,
inclusive.

2. Female subjects of nonchildbearing potential must meet at least 1 of the following
criteria:

1. Achieved postmenopausal status, defined as follows: cessation of regular menses
for at least 12 consecutive months with no alternative pathological or
physiological cause; with a serum follicle-stimulating hormone (FSH) level
confirming the postmenopausal state;

2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;

3. Have medically confirmed ovarian failure. All other female subjects (including
females with tubal ligations) are considered to be of childbearing potential.

3. Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).

4. Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legal representative) has been informed of all pertinent aspects of
the study.

5. Subjects who are willing and able to comply with all scheduled visits, treatment plan,
laboratory tests, and other study procedures.

Additional Inclusion Criteria for Subjects With Normal Hepatic Function:

Subjects in the normal hepatic function cohort (Cohort 3) must be considered healthy and
meet all of the following additional inclusion criteria to be eligible for enrollment into
the study:

1. No known or suspected hepatic impairment based on liver function tests, albumin and
prothrombin time, defined as the following:

1. ALT and AST

2. Total bilirubin have direct bilirubin measured and would be eligible for this study provided the
direct bilirubin level is not greater than 0.5 mg/dL;

3. Alkaline phosphatase

4. Albumin within the normal range (local lab ranges);

5. Prothrombin time (PT) within the normal range (local lab ranges).

2. Subjects must fit the demographic-matching criteria, including:

1. A total body weight that is +/- 10 kg of the population median of the pooled
hepatic impairment cohorts (Cohorts 1 and 2).

2. An age that is +/- 5 years of the population median of the pooled hepatic
impairment cohorts (Cohorts 1 and 2).

3. No known or suspected hepatic impairment.

4. Healthy is defined as no clinically relevant abnormalities identified by a detailed
medical history, full physical examination, including blood pressure (BP) and pulse
rate (PR) measurement, 12 lead ECG or clinical laboratory tests.

Additional Inclusion Criteria for Subjects with Impaired Hepatic Function:

Subjects in the hepatic impairment cohorts (Cohorts 1 and 2) must meet the following
additional inclusion criteria to be eligible for enrollment into the trial:

1. Satisfy the criteria for Class B, or C of the modified Child-Pugh Classification.

2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to
any acute ongoing hepatocellular process) documented by medical history, physical
examination, liver biopsy, hepatic ultrasound, computerized tomography (CT) scan, or
magnetic resonance imaging (MRI).

3. Known stable hepatic impairment, defined as no evidence of clinically significant
change in disease status within the last 30 days, as documented by the subject's
recent medical history (eg, no worsening clinical signs of hepatic impairment, or no
worsening of total bilirubin or prothrombin time by more than 50%).

4. Stable drug regimen defined as not starting a new drug or changing dosage within seven
days or five half-lives (whichever is longer) prior to the dosing of investigational
product. History of alcohol abuse is permissible providing that the results of alcohol
test are negative at Screening and on Day -1, and the subject is willing and able to
abide by the lifestyle guidelines.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Any condition possibly affecting drug absorption (eg, gastrectomy).

2. A positive urine drug test. Subjects with hepatic impairment (Cohorts 1 and 2) will be
eligible to participate if their urine drug test is positive with a drug for a
prescribed substance that is not expected to interfere with the PK of glasdegib.

3. Pregnant female subjects; breastfeeding female subjects; fertile male subjects who are
unwilling or unable to use at least one highly effective method of contraception as
outlined in this protocol for the duration of the study and for at least 90 days after
the glasdegib dose and, refrain from sperm donation for the duration of the Study and
for at least 90 days after the glasdegib dose.

4. History of sensitivity to heparin or heparin-induced thrombocytopenia.

5. Blood donation of approximately 1 pint (500 mL) or more within 56 days prior to
dosing.

6. Unwilling or unable to comply with the Lifestyle Requirements.

7. Subjects who are investigational site staff members directly involved in the conduct
of the study and their family members, site staff members otherwise supervised by the
investigator, or subjects who are Pfizer employees directly involved in the conduct of
the study.

8. History of known sensitivity to glasdegib.

9. Treatment with an investigational drug within 30 days (or as determined by the local
requirement) or 5 half-lives preceding the dose of glasdegib (whichever is longer).

10. Subjects with a history of or current positive results for human immunodeficiency
virus (HIV).

11. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or laboratory abnormality that may increase the
risk associated with study participation or investigational product administration or
may interfere with the interpretation of study results and, in the judgment of the
investigator, would make the subject inappropriate for entry into this study.

Additional Exclusion Criteria for Subjects with Normal Hepatic Function:

In addition, subjects in the normal hepatic function cohort (Cohort 3) presenting with any
of the following will not be included in the trial:

1. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies deemed relevant for participation in this
study, but excluding untreated, asymptomatic, seasonal allergies at the time of
dosing).

2. History of regular alcohol consumption exceeding 7 drinks/week for females or 14
drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.

3. Screening supine BP => 140 mm Hg (systolic) or => 90 mm Hg (diastolic), following at
least 5 minutes of supine rest. If BP is => 140 mm Hg (systolic) or => 90 mm Hg
(diastolic), the BP should be repeated two more times and the average of the three BP
values should be used to determine the subject's eligibility.

4. 12-lead ECG demonstrating QTcF >450 msec or a QRS interval >120 msec at Screening. If
QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more
times and the average of the three QTcF or QRS values should be used to determine the
subject's eligibility.

5. Use of prescription or nonprescription drugs and dietary supplements within 7 days or
5 half-lives (whichever is longer) prior to the first dose of lasdegib. As an
exception, acetaminophen/paracetamol may be used at doses of = nonprescription medications that are not believed to affect subject safety or the
overall results of the study may be permitted on a case by case basis following
approval by the sponsor. Herbal supplements and hormone replacement therapy must have
been discontinued at least 28 days prior to the dose of investigational product.

6. Subjects with a history of or current positive results for hepatitis B or hepatitis C,
including hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb),
or hepatitis C antibody (HCVAb).

Additional Exclusion Criteria for Subjects With Impaired Hepatic Function:

In addition, subjects in the hepatic impairment cohorts (Cohorts 1 and 2) presenting with
any of the following will not be included in the trial:

1. Other clinically significant disease that contraindicates study drug or that may
affect the PK of glasdegib (stable, chronic, controlled disorders such as hypertension
and diabetes may be acceptable).

2. Hepatic carcinoma and hepatorenal syndrome or life expectancy

3. Undergone porta-caval shunt surgery. NOTE: Subjects with a transjugular intrahepatic
portosystemic shunt (TIPS) are permitted provided that they meet the Child-Pugh
Classification criteria

4. History of gastrointestinal hemorrhage either due to esophageal varices or peptic
ulcers less than one month prior to study entry.

5. Any clinically significant laboratory abnormality except for those parameters
influenced by hepatic impairment. Due to potential for alteration of hepatic function
in renally impaired patients, subjects must have an estimated glomerular filtration
rate (eGFR) corrected for their body surface area of => 75 mL/min based on the
Modification of Diet in Renal Disease (MDRD) equation, with a single repeat permitted
to assess eligibility, if needed.

6. Presence of clinically active stage 3 or 4 encephalopathy.

7. Severe uncontrolled ascites and/or pleural effusion.

8. Screening blood pressure => 160 mm Hg (systolic) or => 90 mm Hg (diastolic), following
at least 5 minutes of supine rest. If initial BP is => 160 mm Hg (systolic) or => 90
mm Hg (diastolic), the BP should be repeated two more times and the average of the
three BP values should be used to determine the subject's eligibility.

9. Screening supine 12-lead ECG demonstrating QTcF >470 msec or a QRS interval >120 msec.
If initial QTcF exceeds 470 msec, or QRS exceeds 120 msec, the ECG should be repeated
two more times and the average of the three QTcF or QRS values should be used to
determine the subject's eligibility.

10. Use of food, drugs, or dietary supplements that may affect the PK of glasdegib within
7 days or 5 half-lives (whichever is longer) prior to the dose of glasdegib. Use of
medications that are not believed to affect subject safety and are medically necessary
for the treatment and maintenance of hepatic disease and other pre-existing and/or
concurrent stable comorbid conditions are permitted with approval by the sponsor.
Limited use of nonprescription medications that are not believed to affect subject
safety or the overall results of the study may be permitted on a case by case basis
with approval by the sponsor. Herbal supplements and hormone replacement therapy must
have been discontinued at least 28 days prior to the dose of investigational product.

11. Concurrent use of any of the following food or drugs known to inhibit CYP3A4 (consult
the sponsor if in doubt whether a food or a drug falls into any of the above
categories) within 7 days or 5 half-lives (whichever is longer) prior to the dose of
glasdegib, until the completion of the last PK sample collection. Use of strong or
moderate CYP3A4 inhibitors includes but is not limited to: amprenavir, aprepitant,
atazanavir, boceprevir, ciprofloxacin, clarithromycin, conivaptan, darunavir,
delavirdine, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, indinavir,
itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir,
posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, troleandomycin,
verapamil, voriconazole, grapefruit juice or grapefruit/grapefruit-related citrus
fruits (eg, Seville oranges, pomelos). The topical use of these medications (if
applicable), such as 2% ketoconazole cream, is allowed. All concomitant medications
must be approved by the sponsor.

12. Concurrent use of any of the following food or drugs known to induce CYP3A4 (consult
the sponsor if in doubt whether a food or a drug falls into any of the above
categories) within 12 days or 5 half-lives (whichever is longer) prior to the dose of
investigational product, until the completion of the last PK sample collection. Strong
or moderate CYP3A4 inducers includes but is not limited to: avasimibe, bosentan,
carbamazepine, efavirenz, etravirine, felbamate, modafinil, nafcillin, nevirapine,
phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John's
wort. All concomitant medication must be approved by the sponsor.

13. Subjects with congenital long QT syndrome, medical history of Torsades de Pointes or
clinically significant ventricular arrhythmias.

14. Use of PPIs, including but not limited to esomeprazole, lansoprazole, omeprazole,
pantoprazole, and rabeprazole, within 5 days prior to the day of glasdegib dose (Day
1).

15. Subjects will abstain from taking lactulose or other medications which could result in
diarrhea or have excessive (>2) bowel movements per day within 12 hours prior to
glasdegib dosing and 12 hours post dosing.

NCT03627754
Pfizer
Not yet recruiting
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Hepatic Impairment
NCT03626415
All Genders
18+
Years
Multiple Sites
Hepatic Impairment
NCT03660241
All Genders
18+
Years
Orlando, Florida
Renal Impairment
NCT03542305
All Genders
18+
Years
Multiple Sites
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib
A Phase 1, Open Label, Single Dose, Parallel Group Study To Evaluate The Plasma Pharmacokinetics Of Glasdegib (Pf-04449913) In Healthy Subjects With Normal Hepatic Function And In Subjects With Impaired Hepatic Function
This is a Phase 1, open-label, parallel group, single dose study to investigate the effect of moderate or severe hepatic impairment on the PK of glasdegib, compared to subjects with normal hepatic function.
This is a Phase 1, open-label, parallel group, single dose study to investigate the effect of hepatic impairment on the PK of glasdegib after administration of a single oral 100 mg dose. Subjects with moderate or severe hepatic impairment will be enrolled, followed by healthy subjects with normal hepatic function who serve as matched controls.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Hepatic Impairment
Drug: Glasdegib 100 mg single oral dose
A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.
  • Experimental: Moderate Hepatic Impairment Group
    Subjects with Child-Pugh Classification B (score 7-9)
    Intervention: Drug: Glasdegib 100 mg single oral dose
  • Experimental: Severe Hepatic Impairment Group
    Subjects with Child-Pugh Classification C (score 10-15)
    Intervention: Drug: Glasdegib 100 mg single oral dose
  • Experimental: Normal Hepatic Function Group
    Healthy subjects with normal hepatic function
    Intervention: Drug: Glasdegib 100 mg single oral dose
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
24
Same as current
November 28, 2019
November 28, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy or hepatically impaired female subjects of non-child bearing potential and/or male subjects who, at the time of Screening, are between the ages of 18 and 75 years, inclusive.
  2. Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:

    1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; with a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state;
    2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    3. Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations) are considered to be of childbearing potential.
  3. Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
  4. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
  5. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Additional Inclusion Criteria for Subjects With Normal Hepatic Function:

Subjects in the normal hepatic function cohort (Cohort 3) must be considered healthy and meet all of the following additional inclusion criteria to be eligible for enrollment into the study:

  1. Liver function tests, albumin and prothrombin time must be within normal range (local lab ranges).
  2. Subjects must fit the demographic-matching criteria, including:

    1. A total body weight that is +/- 10 kg of the population median of the pooled hepatic impairment cohorts (Cohorts 1 and 2).
    2. An age that is +/- 5 years of the population median of the pooled hepatic impairment cohorts (Cohorts 1 and 2).
  3. No known or suspected hepatic impairment.
  4. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure (BP) and pulse rate (PR) measurement, 12 lead ECG or clinical laboratory tests.

Additional Inclusion Criteria for Subjects with Impaired Hepatic Function:

Subjects in the hepatic impairment cohorts (Cohorts 1 and 2) must meet the following additional inclusion criteria to be eligible for enrollment into the trial:

  1. Satisfy the criteria for Class B, or C of the modified Child-Pugh Classification.
  2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, computerized tomography (CT) scan, or magnetic resonance imaging (MRI).
  3. Stable hepatic impairment, defined as no clinically significant change in disease status within the last 30 days, as documented by the subject's recent medical history (eg, no worsening clinical signs of hepatic impairment, or no worsening of total bilirubin or prothrombin time by more than 50%).
  4. Stable drug regimen defined as not starting a new drug or changing dosage within seven days or five half-lives (whichever is longer) prior to the dosing of investigational product. History of alcohol abuse is permissible providing that the results of alcohol test are negative at Screening and on Day -1, and the subject is willing and able to abide by the lifestyle guidelines.

Exclusion Criteria:

  1. Any condition possibly affecting drug absorption (eg, gastrectomy).
  2. A positive urine drug test. Subjects with hepatic impairment (Cohorts 1 and 2) will be eligible to participate if their urine drug test is positive with a drug for a prescribed substance that is not expected to interfere with the PK of glasdegib.
  3. Pregnant female subjects; breastfeeding female subjects; fertile male subjects who are unwilling or unable to use at least one highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the glasdegib dose and, refrain from sperm donation for the duration of the Study and for at least 90 days after the glasdegib dose.
  4. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  5. Blood donation of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  6. Unwilling or unable to comply with the Lifestyle Requirements.
  7. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees directly involved in the conduct of the study.
  8. History of known sensitivity to glasdegib.
  9. Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the dose of glasdegib (whichever is longer).
  10. Subjects with a history of or current positive results for human immunodeficiency virus (HIV).
  11. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Additional Exclusion Criteria for Subjects with Normal Hepatic Function:

In addition, subjects in the normal hepatic function cohort (Cohort 3) presenting with any of the following will not be included in the trial:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies deemed relevant for participation in this study, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
  3. Screening supine BP => 140 mm Hg (systolic) or => 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is => 140 mm Hg (systolic) or => 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
  4. 12-lead ECG demonstrating QTcF >450 msec or a QRS interval >120 msec at Screening. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF or QRS values should be used to determine the subject's eligibility.
  5. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of lasdegib. As an exception, acetaminophen/paracetamol may be used at doses of =<1 g/day. Limited use of nonprescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case by case basis following approval by the sponsor. Herbal supplements and hormone replacement therapy must have been discontinued at least 28 days prior to the dose of investigational product.
  6. Subjects with a history of or current positive results for hepatitis B or hepatitis C, including hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb).
  7. Subjects with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:

    1. AST or ALT level > upper limit of normal (ULN);
    2. Total bilirubin level => 1.5 × ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is not greater than 0.5 mg/dL.

Additional Exclusion Criteria for Subjects With Impaired Hepatic Function:

In addition, subjects in the hepatic impairment cohorts (Cohorts 1 and 2) presenting with any of the following will not be included in the trial:

  1. Other clinically significant disease that contraindicates study drug or that may affect the PK of glasdegib (stable, chronic, controlled disorders such as hypertension and diabetes may be acceptable).
  2. Hepatic carcinoma and hepatorenal syndrome or life expectancy <1 year.
  3. Undergone porta-caval shunt surgery. NOTE: Subjects with a transjugular intrahepatic portosystemic shunt (TIPS) are permitted provided that they meet the Child-Pugh Classification criteria
  4. History of gastrointestinal hemorrhage either due to esophageal varices or peptic ulcers less than one month prior to study entry.
  5. Any clinically significant laboratory abnormality except for those parameters influenced by hepatic impairment. Due to potential for alteration of hepatic function in renally impaired patients, subjects must have an estimated glomerular filtration rate (eGFR) corrected for their body surface area of => 75 mL/min based on the Modification of Diet in Renal Disease (MDRD) equation, with a single repeat permitted to assess eligibility, if needed.
  6. Presence of clinically active stage 3 or 4 encephalopathy.
  7. Severe uncontrolled ascites and/or pleural effusion.
  8. Screening blood pressure => 160 mm Hg (systolic) or => 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial BP is => 160 mm Hg (systolic) or => 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
  9. Screening supine 12-lead ECG demonstrating QTcF >470 msec or a QRS interval >120 msec. If initial QTcF exceeds 470 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF or QRS values should be used to determine the subject's eligibility.
  10. Use of food, drugs, or dietary supplements that may affect the PK of glasdegib within 7 days or 5 half-lives (whichever is longer) prior to the dose of glasdegib. Use of medications that are not believed to affect subject safety and are medically necessary for the treatment and maintenance of hepatic disease and other pre-existing and/or concurrent stable comorbid conditions are permitted with approval by the sponsor. Limited use of nonprescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case by case basis with approval by the sponsor. Herbal supplements and hormone replacement therapy must have been discontinued at least 28 days prior to the dose of investigational product.
  11. Concurrent use of any of the following food or drugs known to inhibit CYP3A4 (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 7 days or 5 half-lives (whichever is longer) prior to the dose of glasdegib, until the completion of the last PK sample collection. Use of strong or moderate CYP3A4 inhibitors, includes but is not limited to amprenavir, aprepitant, atazanavir, boceprevir, ciprofloxacin, clarithromycin, conivaptan, darunavir, delavirdine, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole, grapefruit juice or grapefruit/grapefruit-related citrus fruits (eg, Seville oranges, pomelos). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed. All concomitant medications must be approved by the sponsor.
  12. Concurrent use of any of the following food or drugs known to induce CYP3A4 (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days or 5 half-lives (whichever is longer) prior to the dose of investigational product, until the completion of the last PK sample collection. Strong or moderate CYP3A4 inducers, includes but are not limited to avasimibe, bosentan, carbamazepine, efavirenz, etravirine, felbamate, modafinil, nafcillin, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John's wort. All concomitant medication must be approved by the sponsor.
  13. Subjects with congenital long QT syndrome, medical history of Torsades de Pointes or clinically significant ventricular arrhythmias.
  14. Use of PPIs, including but not limited to esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole, within 5 days prior to the day of glasdegib dose (Day 1).
  15. Subjects will abstain from taking lactulose or other medications which could result in diarrhea or have excessive (>2) bowel movements per day within 12 hours prior to glasdegib dosing and 12 hours post dosing.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
Yes

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Not Provided
 
 
NCT03627754
B1371016
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now